Supplement Industry Critics On Agenda For FDA's Ingredient List Meeting
This article was originally published in The Rose Sheet
FDAs Oct. 3 meeting agenda includes Pieter Cohen, Harvard Medical School professor; Consumers Union Programs Director Chuck Bell; Laura MacCleery, Center for Science in the Public Interest regulatory affairs director; and Stephanie Scarmo, Pew Charitable Trusts Health Care Products Project officer.
You may also be interested in...
FDA agrees with public health advocates that ingredients should be on a potential list of those available when Congress passed DSHEA only after current substantiation for a reasonable expectation of safety for their intended uses.
CFSAN hosts a discussion at its College Park, Md., headquarters on developing a list of dietary ingredients available in the US food supply before Congress passed DSHEA. Food and drug law attorneys Todd Harrison and Wes Siegner make arguments that FDA is heading in the wrong direction to keep violative ingredients off the market.
Cannabidiol is found in the hemp plant and other sources and is not an intoxicant, but a "human neurotransmitter and a normal part of the cannabidiol neurotransmitter system in the human body," says "Vitamin Lawyer" Ralph Fucetola.